Psyence Biomedical Ltd Common Shares

Yahoo Finance • 18 days ago

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs,... Full story

Yahoo Finance • 2 months ago

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine therapies for unmet mental health needs,... Full story

Yahoo Finance • 5 months ago

Unusual volume stocks in Monday's session

Unusual volume stocks are being observed in Monday's session. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT PBM [https://www.chartmill.com/stock/quote/PBM/profile] 76.28% PSYENCE BIOMEDICAL LTD (NASDAQ:P... Full story

Yahoo Finance • 5 months ago

Corporate Update, August 2025

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ: PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop safe, effective, and naturally derived p... Full story

Yahoo Finance • 5 months ago

Psyence Biomedical stock soars after partner achieves ibogaine breakthrough

Investing.com -- Psyence Biomedical Ltd. (NASDAQ:PBM) stock surged 70% after the company announced that its strategic partner, PsyLabs, successfully produced a GMP-aligned Ibogaine Total Alkaloid extract. The high-purity extract met all m... Full story

Yahoo Finance • 5 months ago

PsyLabs produces GMP-aligned ibogaine extract, meeting safety standards

NEW YORK - Psyence Biomedical Ltd. (NASDAQ:PBM), a micro-cap biotech company with a market capitalization of $3.15 million, announced Thursday that its strategic partner PsyLabs has successfully produced a GMP-aligned Ibogaine Total Alkalo... Full story

Yahoo Finance • 5 months ago

Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compoun... Full story

Yahoo Finance • 6 months ago

Psyence Biomedical regains Nasdaq compliance after reverse split

NEW YORK - Psyence Biomedical Ltd. (NASDAQ: PBM), currently trading at $4.37 with a market capitalization of $2.55 million, has regained compliance with all Nasdaq continued listing requirements following a hearing on May 29, the company a... Full story

Yahoo Finance • 8 months ago

Psyence Group Announces Share Consolidation

TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. ("Psyence Group" or the "Company") (CSE: PSYG), announces that the Company will be consolidating all of its issued and outstanding share capital (the "Common Shares") on the... Full story

Yahoo Finance • 9 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein

TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced tha... Full story

Yahoo Finance • 10 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced tha... Full story